Genia Turanova, Chief Investment Strategist for Game-Changing Stocks and Fast-Track Millionaire, is a financial writer and money manager whose experience includes serving for more than a decade as a portfolio manager and Investment Committee member for a New York-based money management firm. Genia also researched, wrote and managed recommendations for several investment advisories. From 2011 to 2016, she served as Editor of the award-winning Leeb Income Performance newsletter. Genia also wrote for The Complete Investor, another award winner, from 2003 to 2016. During that time, Genia was responsible for several portfolios, including the "Income/Value" portfolio and the "FastTrack" portfolio. Genia's academic credentials include an MBA in Finance and Investments from the Zicklin School of Business, Baruch College in New York City. Genia is a CFA Charterholder.
Analyst Articles
With U.S. stocks hitting record highs, investors face a question of where to invest. True, that’s always THE question — but this market isn’t an ordinary one. Expectations for monetary easing have largely been behind the recent strength (up nearly 10% since the beginning… Read More
The market is new all-time highs, unemployment is near its record low, the U.S. economy is in its...
Read More
The market is new all-time highs, unemployment is near its record low, the U.S. economy is in its longest-ever expansion cycle, and the Federal Reserve is discussing a rate cut. Welcome to the new...
Read More
It’s hard to predict whether a stock will do well. Many investors simply follow the trend:...
Read More
It’s hard to predict whether a stock will do well. Many investors simply follow the trend: buying high in order to sell even higher. This momentum strategy is a valid one. Like a freight train,...
Read More
The market is trading near its all-time high, unemployment is near its record low, the U.S. economy is in its longest-ever expansion cycle, and the Fed is discussing a rate cut. Welcome to the new normal. I am not going to… Read More
Not every company is created the same, and not every cybersecurity system works to protect against...
Read More
Not every company is created the same, and not every cybersecurity system works to protect against the same set of threats. For example, some of you may remember Mimecast (Nasdaq: MIME) —...
Read More
Biotech is hot. A number of sizeable deals — and expectations of more — keep the sector...
Read More
Biotech is hot. A number of sizeable deals — and expectations of more — keep the sector in the headlines and in the minds of investors. Just a few days ago, on June 17, Pfizer...
Read More
Every stock tells a tale. Some of these stories are about the changes in the economy and in our habits as consumers. Amazon (Nasdaq: AMZN) is up 11% over the past year and more than 2,000% since 2009 — this reflects the explosive growth… Read More
It’s hard to predict whether a stock will do well. Many investors simply follow the trend: buying high in order to sell even higher. This momentum strategy is a valid one. Like a freight train, a moving stock is hard to stop — there must… Read More
Sarepta Therapeutics (Nasdaq: SRPT), a gene-therapy company and the leader in the treatment of Duchenne muscular dystrophy (DMD) — a rare but deadly disease — looks set to remain on top of the field. On the heels of Pfizer’s (NYSE: PFE) presentation of preliminary data… Read More
Invitae (Nasdaq: NVTA) is set to officially leave behind its earnings-related 24% selloff on May 8. Today’s 10% jump means that in June alone, our genetic testing company rallied 36%, recovering all those losses. One reason for the strong recovery after the disappointing first-quarter results… Read More
